ICER Foresees AstraZeneca’s Tezepelumab for Severe Asthma As Being Only Modestly Cost Effective

September 17, 2021

Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveness at the anticipated price, according to the cost-effectiveness group's calculations.

A Patient-Centric Approach: Care Plans for Patients Pay Off

September 15, 2021

Paula Bickley and Ashleigh Burdette of Biologics by McKesson described a program that identifies 1 in 3 patients as being at risk of nonadherence and then provides support to keep them on track and identify side effects and other problems early.